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Abstract
Purpose The objective of this sub-analysis of the BeCet study
(NCT01136005) was to examine health-related quality of life
(HRQoL) of patients experiencing dermatological adverse
events (AEs) during the first 6 weeks of epidermal growth
factor receptor inhibitor (EGFRI) treatment.
Methods Patients (n=85) treated with EGFRI completed five
questionnaires during the first 6 weeks of treatment. 77 pa-
tients provided enough data for the sub-analysis. Experienced
AEs were reported in the Dermatological Reactions Targeted
Therapy–Patients (DERETT-P), a symptom experience diary
for patients treated with targeted therapy. The impact of
EGFRI-associated dermatological adverse events on HRQoL
was examined using four HRQoL questionnaires; the Func-
tional Assessment of Cancer Therapy–EGFRI (FACT-
EGFRI-18), the Functional Assessment of Cancer Therapy–
General (FACT-G), the 36-Item Short Form Health Survey
(SF-36), and the Skindex-16.
Results During the first 6 weeks of EGFRI treatment, physical
discomfort was the most significantly affected domain. In the
entire study population, xerosis (dry skin) (22.3 %) and pru-
ritus (itchy skin) (16.9 %) were reported as the most impactful
AEs. For patients experiencing a papulopustular eruption
(acneiform rash) pruritus (24.2 %), xerosis (18.9 %), and
papulopustular eruption (6.3 %) were reported as the most
impactful AEs. Papulopustular eruption, xerosis, and pruritus
all showed a significant negative effect on HRQoL, displayed
in FACT-EGFRI-18 scores.
Conclusions In addition to papulopustular eruption, xerosis
and pruritus are major EGFRI-associated dermatological
AEs with an impact on HRQoL, which warrant more attention
in clinical practice and research.
Keywords Cancer . Quality of life . Epidermal growth factor
receptor inhibitor .Papulopustulareruption .Xerosis .Pruritus
Background
Epidermal growth factor receptor inhibitors (EGFRIs) are fre-
quently used in treatment regimens of patients with solid tu-
mors. Compared with cytotoxic chemotherapeutic agents,
which may cause myelosuppression, nausea, vomiting, neu-
ropathy, and alopecia, EGFRIs are associated with a lower
incidence of systemic adverse events (AEs). However, pa-
tients treated with EGFRIs experience dermatological AEs
(dAEs), such as papulopustular eruption (acneiform rash),
xerosis (dry skin), pruritus (itchy skin), and paronychia
(periungual inflammation), as well as mucosal and hair abnor-
malities [1, 2].
The most common AE of EGFRI treatment is a
papulopustular eruption, occurring in 75 to 95 % of patients
[1, 2]. The papulopustular eruption consists of acneiform
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follicular and perifollicular papules and sterile pustules, most
pronounced on the face, scalp, upper back, and chest and is
often accompanied by xerosis and pruri tus . The
papulopustular eruption is a relatively early-onset AE, usually
occurring between 1 to 3 weeks after initiation of treatment.
The incidence is higher with monoclonal antibodies like
cetuximab and panitumumab (more than 88 %) than with
tyrosine kinase inhibitors like gefitinib, erlotinib, lapatinib,
and afatinib (43–75 %). In about 80 to 90 % of the skin reac-
tions, the worst recorded severity is mild (grade 1) to moderate
(grade 2), but in 10 % a more severe skin reaction (grade 3) is
seen [1, 2]. In several studies, the presence and severity of the
eruption has shown a correlation with a positive response to
cancer treatment, as expressed in higher median survival rates
[1–3]. However, patients reported that the papulopustular
eruption interferes in their daily activities and in the appear-
ance of their skin, because the EGFRI-associated dAEs, often
in visible areas, make them worried, frustrated, and depressed
and cause withdrawal from social activities [3, 4].
The physical discomfort caused by EGFRI treatment has
been identified as having the most impact on health-related
quality of life (HRQoL), especially the sensations of pain,
burning, and skin sensitivity. The dAEs may lead to a de-
creased HRQoL and to dose reduction or discontinuation of
anticancer treatment, even though the treatment might be ef-
fective in treating the cancer and reducing the dose may neg-
atively affect cancer outcome [4]. At present, the consequence
of the dAEs on HRQoL in patients with cancer receiving
EGFRI treatment remains poorly understood.
This sub-analysis of the ongoing BeCet study
(NCT01136005) is aimed to provide a better understanding
of HRQoL in patients with cancer receiving EGFRI treatment,
using five different questionnaires.
Patients and materials
Patients
The study population was derived from the ongoing BeCet
study. This phase III randomized double-blinded trial com-
pares Bepanthen against cetomacrogol cream on their preven-
tive effect in decreasing the incidence of grade ≥2 EGFRI-
associated papulopustular eruption and assesses the Dutch
version of Functional Assessment of Cancer Therapy-
EGFRI (FACT-EGFRI-18) for reliability and validity [5, 6].
The study has been approved by the Medical Ethics Review
Committees of each participating hospital. Twelve Dutch cen-
ters are currently recruiting patients starting with an EGFRI
treatment for any type of cancer (i.e., panitumumab,
cetuximab, lapatinib, gefitinib, erlotinib, or afatinib). Patients
need to have an Eastern Co-operative Oncology Group
performance status ≤2 and need to be able to complete
questionnaires.
The first 85 consecutive patients were included for this sub-
analysis between July 2010 andMay 2014. This analysis stud-
ies the impact of the dAEs on the HRQoL, while the main
study analyses the appearance and severity of dAEs. There are
no strict criteria for the sample size in HRQoL studies. Within
a homogenous population there is lower variability in answers
on HRQoL items, making a smaller sample size acceptable.
Materials
During the 6-week study period, patients completed five dif-
ferent questionnaires. They completed the symptom experi-
ence diary Dermatological Reactions Targeted Therapy–Pa-
tients (DERETT-P) and the FACT-EGFRI-18 weekly. Within
the BeCet trial, these two questionnaires are measured weekly
to provide detailed information about the incidence and sever-
ity curve of dAEs. For this sub-analysis, fewer data than in the
main study collected are of relevance. These are the data of
weeks 0, 2, and 4.
In week 4, the Functional Assessment of Cancer Therapy–
General (FACT-G), the 36-Item Short Form Health Survey
(SF-36), and the Skindex-16 questionnaires were completed
for validation purposes of the FACT-EGFRI-18. Week 4 of
treatment was chosen, because then most patients will have
experienced a papulopustular eruption [7]. In this analysis,
scores of these generic questionnaires were compared with
previously published articles, to put the HRQoL of cancer
patients treated with EGFRIs in perspective to similar
samples.
DERETT
The Dermatological Reactions Targeted Therapy (DERETT)
is available in two versions, for patients (DERETT-P) and
healthcare professionals (DERETT-H), consisting of 61 and
50 items, respectively. These tools gather information such as
area involved, severity and duration of the symptoms, prod-
ucts used to treat symptoms, effectiveness of the supportive
care interventions, treatment adherence, and symptom-related
distress [8]. DERETT provides a more precise and clinically
relevant information on the patient’s condition than Common
Terminology Criteria for Adverse Events (CTCAE) grading
alone.
FACT-EGFRI-18
The Functional Assessment of Cancer Therapy Question-
naire–EGFRI has been developed to assess HRQoL related
to EGFRI-associated dAEs. The translation, linguistic valida-
tion, and qualitative assessment of the FACT-EGFRI-18 have
been described [5, 6, 9]. The validations of the English and
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Dutch versions are ongoing. The FACT-EGFRI-18 consists of
18 items in three HRQoL domains: physical (7 items), social/
emotional (6 items), and functional (5 items). Scores are rated
on a numerical analogue scale (0=not at all, 4=very much). A
high domain score reflects a lowHRQoL. On the other hand, a
high total score indicates a high HRQoL [10].
FACT-G
The FACT-G version 4 is a patient reposted outcome (PRO)
measure with numerical analogue scales (0=not at all, 4=very
much). The FACT-G version 4 consists of 27 items in four
HRQoL domains: physical (7 items), social/family (7 items),
emotional (6 items), and functional well-being (7 items). High
total scores indicate a high HRQoL. The FACT-G has been
validated for patients with cancer in general [11].
SF-36
The 36-Item Short Form Health Survey (SF-36) is a generic
HRQoL survey. The questionnaire consists of 36 items, cov-
ering eight scales: physical functioning, role limitations due to
physical health and due to emotional problems, energy/fa-
tigue, emotional well-being, social functioning, pain, and gen-
eral health. A high total scale score represents a high HRQoL.
The SF-36 can be used to measure HRQoL in general and
specific populations, and has been validated for Dutch citi-
zens, and patients with cancer [12].
Skindex-16
The Skindex-16 is a 16-item PRO assessing dermatological
symptoms on a numerical analogue scale (0=never bothered,
6=always bothered), where high scores represent a low
HRQoL. It contains three domains: symptoms (4 items), emo-
tions (7 items), and functioning (5 items). The Skindex-16 is
reliable and valid for general skin diseases. It has been used
more often to assess HRQoL in patients receiving EGFRI treat-
ment, but does not address symptoms related to hair, nails, or
mucous membranes, that are specific targets for EGFRIs [13].
Statistical analysis
Descriptive statistics were used to describe the study popula-
tion. In DERETT-P, the incidences of the AEs with the highest
impact on HRQoL (Fig. 1) were determined per week and in
total. The domain and total scores of FACT-EGFRI-18 during
the first 6 weeks of EGFRI treatment are displayed in a time
plot (Fig. 2). With a one-way ANOVA, item and domain
scores during treatment were compared to baseline, followed
by a Bonferroni procedure to correct for multiple testing.
Using the Mann–Whitney test, FACT-EGFRI-18 scores
during week 2 to 4 and Skindex-16 scores of week 4 were
compared between different subgroups, i.e., gender, type of
cancer, EGFRI agent, and age, as mainly in those weeks
papulopustular eruption manifests [1]. To analyze HRQoL
for patients experiencing a papulopustular eruption, their
FACT-EGFRI-18 scores were compared with pre-treatment
scores, also using the Mann–Whitney test. With manual
two-sample t tests and one-sample Wilcoxon signed-rank
tests, mean and median scores of FACT-G, SF-36, and
Skindex-16 were both compared to scores in previously pub-
lished articles, in order to determine how HRQoL relates to
these populations. DERETT-P and FACT-EGFRI-18 scores
have not been described before and could, therefore, not be
compared. All data analysis was performed with the Statistical
Package for Social Sciences (SPSS) version 20. Overall,
p<0.05 was accepted as a statistically significant result.
Results
Demographics
Between July 2010 and May 2014, a total of 85 patients were
included. Eight patients (9.4 %) with disease progression were
excluded as they stopped EGFRI treatment before week 4 and,
consequently, did not complete FACT-G, SF-36, and Skindex-
16. In total, 77 patients were evaluable. Six (7.79 %) of them
stopped EGFRI treatment after week 4 because of disease pro-
gression and/or death, but produced enough data to be consid-
ered evaluable for this study. The mean age of the included
study population (n=77) was 65.0 years (SD 9.91). Forty-six
patients (59.7 %) were male. The majority of the patients were
of Caucasian origin (96.1 %) and three patients of other origin
(Asian and Hindu) (Table 1). Patients were mainly diagnosed
with non-small cell lung cancer (NSCLC) and colorectal can-
cer, 41.6 and 39.0 %, respectively. Panitumumab (37.7 %) and
erlotinib (32.5 %) were the most prescribed EGFRI drugs. Of
the DERETT-P, FACT-EGFRI-18, FACT-G, SF-36, and
Skindex-16 questionnaires, 50, 47.4, 25.9, 25.9, and 23.5 %,
respectively, were not completed. The main reasons for the
uncompleted questionnaires were that the healthcare provider
did not hand out the questionnaire in the uneven weeks (weeks
1, 3, and 5) and early discontinuation due to disease progres-
sion. Some patients did not complete the questionnaires be-
cause they did not feel the need to do so since their AEs stayed
almost the same as during the previous measures, most prom-
inent in patients with many or nearly none experienced AEs.
Patient burden and burn out may also play a role.
Impact of various adverse events
The DERETT-P questionnaire asks patients to report if they
experienced certain AEs and in which severity. Secondly, the
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questionnaire asks from which AE they experienced the most
hinder. Xerosis and pruritus were reported most often: mean
22.3 and 16.9 %, respectively. The remaining dAEs were re-
ported by means less than 4.8 %. Fig. 1a displays the inci-
dence of the four AEs which have the highest impact on
HRQoL during the 6-week study period, while Fig. 1b dis-
plays the AEs with the highest impact on HRQoL over time.
The peak of impact of xerosis on HRQoL was in week 5
(33.3 %), and at week 6 for pruritus (25.0 %). Papulopustular
eruption was reported as having the most impact on HRQoL
by 4.2 % of all patients, with a peak in week 4 (9.4 %).
Since a papulopustular eruption may overlap xerosis and
pruritus and, therefore, the outcome may be different in pa-
tients who did develop a papulopustular eruption compared to
those who did not, we explored the patients that experienced a
papulopustular eruption separately. Even in this subgroup,
AEs having most impact on HRQoL remained pruritus
(24.2 %), xerosis (18.9 %), a burning sensation of the skin
(8.4 %), and lastly a papulopustular eruption (6.3 %).
Quality of life during EGFRI treatment
Table 2 and Fig. 2 show the development of total and domain
scores of FACT-EGFRI-18 over time. Scores on the physical
domainwere significantly higher during all 6 weeks compared
to baseline (p<0.001). The functional domain for all grades
showed a significantly higher score in the sixth week com-
pared to baseline (p=0.039). In patients with grade 1/2, the
dispersion in these domains is relatively low (Fig. 2c). How-
ever, the social-emotional domain did show significant chang-
es within the grade 3/4 sample (Fig. 2d).What stands out is the
large spread on the domains of Bsocial-emotional^ and
Bfunctional^ in patients with grade 3/4 at weeks 0 and 1. This
was also the case prior to the start of the EGFRI treatment; in
week 0, the standard error is negative and as the weeks pass
this spread decreases. For all domains and items, a higher score
represents lower HRQoL. The total FACT-EGFRI-18 score
decreased during treatment, reflecting decrease in HRQoL.
There were no significant differences between FACT-
EGFRI-18 scores for gender (total score men 63.40, women
63.92) or cancer type (total scores ranging from 63.7 to
68.00). Patients younger than 50 years scored significantly
(p=0.015) lower on the functional domain (score 0.91
<50 years versus 1.61 61–70 years (mean age)). Patients
above 81 years experienced more impact on the physical do-
main (p=0.028) (2.94 versus 5.06 in the mean age group of
61–70) and total score (p=0.020) (68.56 by >81; 63.84 by 61–
70), compared to patients in the mean age range between 61
and 70 years.
The presence of papulopustular eruption during the study
period significantly decreased HRQoL as measured by FACT-
EGFRI-18 (p<0.001). This was most prominent for the phys-
ical domain (Table 3). FACT-EGFRI-18 scores were also an-
alyzed separately for xerosis and pruritus, showing a signifi-
cant reduced HRQoL (p<0.014).
FACT-G scores were comparedwith the scores of Cella et al.
[11], which included other types of cancer, i.e., leukemia, lym-
phoma, prostate cancer, and ovarian cancer without EGFRI
treatment. Our study population scored significantly higher on
the physical (p=0.014) and emotional domains (p=0.013), with
higher scores indicating a higher HRQoL. Scores on the social-
family and functional domains did not differ significantly.
Scores on SF-36 were first compared to scores of a sample
of a Dutch healthy control population in order to examine the
difference in HRQoL of EGFRI treated cancer patients with
healthy individuals [14]. The current study population had a
higher mean age and scored significantly lower on all domains
(p<0.028), meaning lower HRQoL. Secondly, SF-36 scores
were compared with a group of cancer patients about to start
chemotherapy or radiotherapy. The current study population
was older, consisted of fewer females, had more patients with
NSCLC and colorectal cancer, and fewer with breast cancer.
Scores were similar for most SF-36 domains. Only for phys-
ical functioning (p=0.042) and general health (p<0.001), the
current study population scored significantly lower, meaning a
lower HRQoL [14].
Skindex-16 separately identified a significant lower total
score when papulopustular eruption was present (p<0.002),
Table 1 Patient demographics (n=77)





















SD standard deviation,NSCLC non-small cell lung cancer,HNC head and
neck cancer
a Expressed in mean (SD) [range]
516 Support Care Cancer (2016) 24:513–521
but not for the presence of xerosis or pruritus. The Skindex-16
scores did not differ significantly between patients experienc-
ing papulopustular eruption, xerosis, or pruritus (Table 4).
The current Skindex-16 scores were compared with the
data of Joshi et al. [4] and Rosen et al. [15], both a retrospec-
tive investigation of Skindex-16 scores of patients with dAEs
due to cancer treatment in a specialty referral clinic. The study
of Joshi et al. is the most comparable to the current study as
they focused on patients treated with EGFRIs. Joshi et al. [4]
analyzed more women, more patients younger than 50 years,
and more patients treated with cetuximab and erlotinib. Rosen
et al. [15] included patients with targeted as well as non-
targeted therapy, who were generally younger, more often
female, and less often of Caucasian ethnicity. Our study pa-
tients with papulopustular eruption and xerosis scored higher
HRQoL on all Skindex-16 domains as patients in Joshi et al.
[4] (p<0.001) and in Rosen et al. [15] (p<0.032). This was
most marked on the emotional level. Our patients with pruri-
tus had equal scores on the physical domain compared to both
studies, and a comparable score on the functional domain with
patients in Rosen et al. [15] receiving non-targeted therapy
(Table 4). Even though not significant in the relatively small
sample size, patients with pruritus showed a trend of higher
scores on Skindex-16 and FACT-EGFRI-18 (indicating a low-
er HRQoL) than patients with papulopustular eruption or
xerosis.
Discussion
The current results show that xerosis and pruritus have a major
negative impact on HRQoL during the first 6 weeks of EGFRI
treatment. This also applies for the patients affected by
papulopustular eruption, from which only 6.3 % report the
presence of papulopustular eruption as having the highest im-
pact on HRQoL. These findings were confirmed also in the
STEPP trial [16, 17].
In Gandhi et al. [18], patients reported xerosis as having the
most negative impact on HRQoL and pruritus as the third
most impactful of all dAEs. In addition, xerosis was reported
as having the second most negative impact on HRQoL of all
unexpected AEs due to cancer treatment. Since xerosis and
pruritus are less frequent reported EGFRI-associated dAEs,
not all patients are counseled about these possible dAEs be-
fore initiating treatment. Therefore, they cannot engage in
Fig 1 a Adverse events that patients reported as present in DERETT-P
compared to b adverse events as having most impact on HRQoL as
measured by DERETT-P. In (a), papulopustular eruption is reported as
the most common adverse event, while (b) displays that xerosis and
pruritus have a more profound impact on HRQoL. HRQoL health-
related quality of life
Table 2 Domain and total scores FACT-EGFRI-18 per week







0 1.41 (1.80) 0.490 (2.20) 0.470 (1.69) 69.5 (5.23)
1 2.90 (3.49) 1.29 (2.80) 0.760 (2.21) 67.0 (8.03)
2 5.42 (4.13) 1.45 (2.01) 1.200 (1.86) 63.8 (7.00)
3 5.32 (4.10) 1.08 (2.10) 0.970 (1.83) 64.6 (6.95)
4 6.00 (5.14) 1.57 (2.60) 1.780 (3.27) 62.6 (9.75)
5 5.41 (4.24) 1.86 (3.02) 1.410 (2.69) 63.2 (8.97)
6 6.65 (5.01) 1.70 (3.28) 1.870 (3.13) 61.6 (10.1)
Scores are presented in mean (standard deviation). Domain scores are
calculated as the sum of all corresponding items, taking into account that
at least 50 % of the items need to be answered for a reliable calculation.
The total score is calculated by subtracting the domain scores from 72 (the
maximum possible total score) and correct for the number of answered
items. Therefore, a low HRQoL is reflected by a high domain score and a
low total score
FACT-EGFRI-18 Functional Assessment of Cancer Therapy–EGFRI
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Fig. 2 aMean (standard error of the mean) FACT-EGFRI-18 total scores
per week. bMean (standard error of the mean) of all grade FACT-EGFRI-
18 domain scores per week. cMean (standard error of the mean) of grade
1/2 FACT-EGFRI-18 domain scores per week. dMean (standard error of
the mean) of grade 3/4 FACT-EGFRI-18 domain scores per week. FACT-
EGFRI-18 Functional Assessment of Cancer Therapy–EGFRI, EGFRI
epidermal growth factor receptor inhibitor
Table 3 HRQoL with papulopustular eruption displayed in FACT-EGFRI-18 scores
Week Papulopustular eruption Domain scores FACT-EGFRI-18
Physical Social-emotional Functional
0 n=0 1.41 (1.80) 0.490 (2.20) 0.470 (1.69)
1 n=19 4.58 (4.03)* 2.21 (3.65)* 1.42 (3.06)*
2 n=31 6.97 (3.70)* 2.00 (2.21)* 1.61 (1.94)*
3 n=24 6.54 (3.98)* 1.50 (2.45)* 1.42 (2.15)*
4 n=30 7.27 (5.75)* 1.77 (2.85)* 2.43 (3.95)*
5 n=19 6.79 (4.13)* 2.37 (3.29)* 1.84 (3.08)*
6 n=24 7.13 (4.16)* 1.92 (2.80)* 1.92 (2.21)*
Scores presented in mean (SD)
FACT-EGFRI-18 Functional Assessment of Cancer Therapy–EGFRI, HRQoL Health-related quality of life
*p<0.05, a significantly lower HRQoL compared with week 0 (baseline)
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anticipatory coping; a method to deal with anticipated AEs. In
an interview study of Frith et al. [19], strategies were identi-
fied for patients to cope with anticipated cancer treatment
AEs. First, patients try to foresee the amount of distress and
accompanying emotions through Baffective rehearsal,^
followed by acceptance of possible AEs and gathering re-
sources to manage them through Bbehavioral rehearsal,^ a
method to modify interpersonal skills and social interactions.
The final strategy is finding ways to control the development
of the AEs and the personal emotional reactions on them [19].
Since this is the first report of FACT-EGFRI-18 scores,
we are not able to compare our data to data from other
trials. Our analysis showed that during the first 6 weeks of
EGFRI treatment, patients experience influence on their
HRQoL primarily due to physical symptoms, especially
irritation, xerosis, pruritus, and nail sensitivity. The re-
versed FACT-EGFRI-18 scores of papulopustular erup-
tion, xerosis and pruritus decreased significantly on the
total scores (p<0.014) indicating a high HRQoL. The
non-reversed FACT-EGFRI-18 scores increased signifi-
cantly on the domain scores (p<0.012) reflecting a low
HRQoL. Only patients experiencing xerosis in week 1 and
patients experiencing pruritus in week 5 did not have a
significant higher score on the functional domain, mean-
ing a non-significant different score compared to before
treatment.
Cella et al. [11] used the FACT-G questionnaire in a
population with different cancer types and treatments, and
EGFRI-treated patients were not included. EGFRI
treatment is considered more tolerable compared to con-
ventional cytotoxic treatments, because systemic AEs are
less frequent [20]. This could explain the higher score on
the physical and emotional domains in the current study
population. Aaronson et al. [14] measured pre-treatment
SF-36 scores, resulting in fewer AEs, which explain a
higher physical functioning and general health.
The study of Joshi et al. [4] analyzed Skindex-16 scores at
any time of AE development instead of the current fixed mea-
surement at week 4 of treatment. In addition, the referral to a
specialty clinic might have increased patients’worry about the
severity of the AEs. Rosen et al. [15] measured patients at any
moment during all types of cancer treatment, causing a
broader range of dAEs, which influences Skindex-16 scores.
This could also explain a better HRQoL for patients with
papulopustular eruption or xerosis. In addition, patients with
pruritus had similar Skindex-16 scores on the physical domain
as the patients in the specialty referral clinic in Joshi et al. [4]
and Rosen et al. [15]. These findings suggest that the impact of
pruritus on HRQoL might be larger than papulopustular erup-
tion and xerosis. The similar score on the physical domain of
Skindex-16 of patients with acne vulgaris suggests clinical
similarities with EGFRI papulopustular eruptions. Patients
with EGFRI-associated papulopustular eruption are generally
more likely to accept the temporary eruption as part of their
treatment for cancer, especially since they are usually in-
formed about its association with effectiveness of treatment,
which can clarify the different impact on emotions and func-
tioning [17, 20, 21].
Table 4 Comparison of mean and median Skindex-16 scores for patients experiencing dermatological adverse events
Skindex-16 domains Current study Current study Current study Joshi et al.4 Rosen et al.14 Rosen et al.14
Papulopustular eruption Xerosis Pruritus EGFRI
AEs
Targeted therapy AEs Non-targeted therapy AEs
n=30 n=24 n=21 n=67 n=163 n=120
Symptoms
Mean (SD) 27.2 (26.4) 22.9 (26.5) 35.6 (28.9) 45.3a,b,c
Median (95 % CI) 20.8 (12.5–33.3) 16.7 (0.00–29.2) 29.2 (20.8–37.5) 37.5 (29.2–54.2)b,c 39.6 (25.0–45.8)b,c
Emotions
Mean (SD) 17.2 (21.9) 14.7 (19.3) 21.4 (24.2) 50.0a,b,c,d
Median (95 % CI) 9.53 (4.77–21.4) 9.53 (0.00–21.4) 14.3 (4.77–26.2) 50.0 (40.5–57.1)b,c,d 38.1 (30.4–47.6)b,c,d
Functioning
Mean (SD) 10.0 (17.1) 7.23 (14.3) 10.5 (15.7) 31.3a,b,c,d
Median (95 % CI) 0.00 (0.00-10.2) 0.00 (0.00–3.34) 3.34 (0.00–16.7) 16.7 (8.2–26.7)b,c,d 13.3 (3.3–20.0)b,c
Joshi et al. [4] displayed mean scores while Rosen et al. [14] displayed median scores. Therefore, in the current study, both are displayed to make
comparison possible
AE adverse event
a No standard deviations were given in Joshi et al. [4]
b A statistically significant result compared with patients from the current study experiencing papulopustular eruption
c A statistically significant result compared with patients from the current study experiencing xerosis
d A statistically significant result compared with patients from the current study experiencing pruritus
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This study required a substantial effort for patients to com-
plete consecutive questionnaires at the intended assessments.
There might be a selection bias as missing data were from
relatively sicker patients, which could result in overestimating
the overall HRQoL and underestimating the impact of dAEs on
HRQoL. Another cause may be the missing data from patients
who did not experience noticeable AE changes and, therefore,
did not complete the questionnaires in the weeks without AE
changes. The incidence of dAEs might be reduced as all pa-
tients received close monitoring and preventive and reactive
treatment. As all factors mentioned above are more likely to
have improved HRQoL of patients, the expectation is that the
current results are indeed realistic and may be even more pro-
found when less confounding factors would be present. Be-
cause the study population consisted mainly of patients from
Caucasian origin, with NSCLC or colorectal cancer, current
results may not apply to all EGFRI-treated cancer patients.
Conclusion
Clinical and research endeavors in patients with various can-
cers who receive medical management consisting of EGFRIs
have focused mainly on papulopustular eruption as an
EGFRI-associated AE, which resulted in an important de-
crease in HRQoL. However, the current study shows that
xerosis and pruritus are also important AEs with a major im-
pact on HRQoL. This justifies more focus on HRQoL related
to these symptoms and on their prevention and treatment in
future research.
In clinical practice, xerosis and pruritus are infrequently
discussed during patient counseling prior to treatment, as they
are less visible than the more common papulopustular erup-
tion. Providing patients adequate information about treatment
and possible AEs has shown a positive result on patients’
emotional and physical well-being. Counseling patients prior
to EGFRI treatment about potential xerosis and pruritus is
therefore important, as well as taking preventive measures
against these AEs [18, 19, 22, 23].
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